Adverse Events to Nontargeted and Targeted Chemotherapeutic Agents Emphasis on Hypersensitivity Responses

作者：Baldo Brian A^*; Pagani Mauro

来源：Immunology and Allergy Clinics of North America, 2014, 34(3): 565-+.

DOI：10.1016/j.iac.2014.04.003

• Cancer drug hypersensitivities
• Chemotherapeutic drug hypersensitivities
• Adverse events to cancer drugs
• Monoclonal antibody adverse events
• Side effects of chemotherapeutic drugs
• Monoclonal antibody hypersensitivities
• Diagnosis of chemotherapeutic drug hypersensitivities
• Desensitization to cancer drugs

Use of cytotoxic agents is associated with potential hypersensitivity reactions which are common with platinum compounds, L-asparaginase, taxanes, procarbazine and epipodophyllotoxins. Mechanisms underlying the reactions may involve IgE, non-allergic or a number of pathogenetically unclear events. Targeted therapies produce less collateral damage but demonstrate their own unique reactions. Cytopenias occur less often and mucocutaneous reactions to EGFR inhibitors, including papulopustular rash, are common. Fifteen currently approved mAbs provoke all four types of hypersensitivities including immune cytopenias, vasculitis, serum sickness and pulmonary events. Some successful desensitization protocols have been developed. Prevention of hypersensitivity reactions is based on skin testing, premedication and/or desensitization.

• 出版日期2014-8
• 单位河北医科大学